Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

GSK and Pfizer remain major players in the global vaccines market as well. Although both companies experienced sales declines in the second quarter due to the COVID-19 pandemic, this should be ...

GlaxoSmithKline and Pfizer are merging their healthcare divisions, creating an over-the-counter drug giant with combined sales of $12.7 billion. The new business will be spun off within three years.

Although Glaxo's plan of action is starting to bear fruit, Pfizer is clearly the better buy here. Unlike Glaxo's, Pfizer's dividend is in no danger whatsoever of a reduction.

GlaxoSmithKline Plc is splitting into two companies and creating a consumer-health joint venture with Pfizer Inc. that will be the world’s biggest supplier of over-the-counter medicines with ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

Pharma giants Pfizer (PFE 1.04%) and GlaxoSmithKline (GSK 0.13%) share similar visions for the future. Both aim to transform into smaller, nimbler biopharmaceutical outfits focused on high-value R&D.